Spots Global Cancer Trial Database for secondary hypogonadism
Every month we try and update this database with for secondary hypogonadism cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism | NCT01534208 | Secondary Hypog... | Androxal | 18 Years - 65 Years | Repros Therapeutics Inc. | |
| Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism | NCT01270841 | Secondary Hypog... | Placebo topical testost... Androxal | 21 Years - 65 Years | Repros Therapeutics Inc. | |
| Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism | NCT00962637 | Secondary Hypog... | Androxal Androxal AndroGel Placebo | 18 Years - 68 Years | Repros Therapeutics Inc. | |
| The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone) | NCT01386606 | Secondary Hypog... | Androxal (enclo... Testosterone | 18 Years - 65 Years | Repros Therapeutics Inc. | |
| Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism | NCT01739595 | Secondary Hypog... | enclomiphene ci... Placebo | 18 Years - 60 Years | Repros Therapeutics Inc. | |
| Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism | NCT00962637 | Secondary Hypog... | Androxal Androxal AndroGel Placebo | 18 Years - 68 Years | Repros Therapeutics Inc. | |
| Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism | NCT01534208 | Secondary Hypog... | Androxal | 18 Years - 65 Years | Repros Therapeutics Inc. | |
| The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone) | NCT01386606 | Secondary Hypog... | Androxal (enclo... Testosterone | 18 Years - 65 Years | Repros Therapeutics Inc. | |
| Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes | NCT00529230 | Advanced Cancer Hypogonadism Pain | Questionnaire Blood draws to ... | 18 Years - | M.D. Anderson Cancer Center | |
| An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism | NCT01739582 | Secondary Hypog... | Androxal | 18 Years - 60 Years | Repros Therapeutics Inc. | |
| Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus | NCT01191320 | Type 2 Diabetes... Secondary Hypog... | Placebo Androxal | 20 Years - 80 Years | Repros Therapeutics Inc. | |
| Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism | NCT01739595 | Secondary Hypog... | enclomiphene ci... Placebo | 18 Years - 60 Years | Repros Therapeutics Inc. | |
| Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism | NCT01067365 | Secondary Hypog... | Androxal Androxal | 18 Years - 68 Years | Repros Therapeutics Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
